Show simple item record

dc.contributor.advisorBritland, Stephen T.
dc.contributor.advisorPicksley, Stephen M.
dc.contributor.advisorEagland, D.
dc.contributor.authorFinter, Wayne*
dc.date.accessioned2011-10-06T15:08:52Z
dc.date.available2011-10-06T15:08:52Z
dc.date.issued2010
dc.identifier.urihttp://hdl.handle.net/10454/5105
dc.description.abstractDue to the safety concerns surrounding viral vectors, non-viral alternatives are desirable for fulfilling the aim of gene therapy. In this project gel mobility shift assays demonstrated how cross-linked PVA nanoparticles successfully form complexes with plasmid DNA and are of a size and charge that should, theoretically, permit endocytosis by eukaryotic cells. However, during in vitro transfection studies no reporter (GFP) gene expression was noted. The collective evidence from electroporation, fluorescent-DNA-tagging, Lipofectin® or calcium phosphate chimeric and chloroquine experiments suggest that a lack of cell uptake is responsible. Nevertheless, the same cross-linked PVA nanoparticles have been shown to exhibit much promise in the field of drug delivery during in vitro experiments, even when used to target the same cell types as those used during transfection studies. Nanagel®, a cross-linked PVA nanoparticle containing budesonide, achieved higher levels of drug delivery than a commercially available form of the same drug (Pulmicort®) after 1 or 24 hours drug exposure. Furthermore, by measuring superoxide production during a stimulated respiratory burst, the budesonide delivered to cells appears fully functional and significantly more effective than Pulmicort® in preventing the formation of reactive oxygen species, following a 24-hour pre-treatment period with the formulation. These findings have exciting possibilities for the use of hard-to-dissolve corticosteroids in the treatment of respiratory disease.en_US
dc.description.sponsorshipAGT Sciences Ltden_US
dc.language.isoenen_US
dc.rights<a rel="license" href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><img alt="Creative Commons License" style="border-width:0" src="http://i.creativecommons.org/l/by-nc-nd/3.0/88x31.png" /></a><br />The University of Bradford theses are licenced under a <a rel="license" href="http://creativecommons.org/licenses/by-nc-nd/3.0/">Creative Commons Licence</a>.en_US
dc.subjectTransfectionen_US
dc.subject; Gene therapyen_US
dc.subject; Drug deliveryen_US
dc.subject; Budesonideen_US
dc.subject; COPDen_US
dc.subject; Asthmaen_US
dc.subject; PVAen_US
dc.subject; Cross-linked PVA nanoparticlesen_US
dc.subject; Plasmid DNAen_US
dc.titleEvaluating the use of cross-linked PVA nanoparticles for gene and drug deliveryen_US
dc.type.qualificationleveldoctoralen_US
dc.publisher.institutionUniversity of Bradfordeng
dc.publisher.departmentMedical Biosciences, School of Life Sciencesen_US
dc.typeThesiseng
dc.type.qualificationnameMPhilen_US
dc.date.awarded2010
refterms.dateFOA2018-07-19T07:07:06Z


Item file(s)

Thumbnail
Name:
Mphil Report Wayne Finter.pdf
Size:
1.129Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record